Epidemiological profile of patients with amiotrophic lateral sclerosis accompanied in the Associação de Assistência à Criança Deficiente
DOI:
https://doi.org/10.11606/issn.2317-0190.v28i1a173469Keywords:
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, EpidemiologyAbstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by irreversible loss of motor neurons in the spinal cord, brainstem and cerebral cortex, leading to muscle atrophy, spasticity and consequently death. Objective: To verify the prevalence of ALS in the Associação de Assistência à Criança Deficiente (AACD) – Ibirapuera’s unit and to characterize the individuals affected by the disease during the rehabilitation process, in order to draw an epidemiological profile of this population. Methods: This is a retrospective study, based on information contained in medical records, referring to a study conducted during the period from January 2008 to January 2018, being a data search guided by a resource developed for this study. Results: The prevalence of patients with ALS in the treatment of neuromuscular diseases is 11.6%. The profile of these patients is slightly higher in white females, with a mean age of 59 years, with systemic arterial hypertension being the most common comorbidity. The most common ALS was sporadic, and Riluzole was the most commonly used drug. There was great variability of physiotherapeutic objectives and an increase in the use of non-invasive mechanical ventilation. There was no association between the presence of gait in the last evaluation and the time of the patient in physical therapy. Conclusion: The objectives are in agreement with the literature, as well as it cites the importance of knowing the population better to have a multidisciplinary approach more suitable for these patients.
Downloads
References
Pradhan J, Noakes PG, Bellingham MC. The Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis. Front Cell Neurosci. 2019;13:368. Doi: https://doi.org/10.3389/fncel.2019.00368
Molteni M, Rossetti C. Neurodegenerative diseases: The immunological perspective. J Neuroimmunol. 2017;313:109-115. Doi: https://doi.org/10.1016/j.jneuroim.2017.11.002
Zapata-Zapata CH, Franco-Dager E, Solano-Atehortua JM, Ahunca-Velasquez LF. Esclerosis lateral amiotrófica: actualización. Iatreia. 2016; 29(2): 904-205. Doi: https://doi.org/10.17533/udea.iatreia.v29n2a08
Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171. Doi: https://doi.org/10.4103/2152-7806.169561
Leite Neto L, Constantine AN. Disartria e qualidade de vida em pacientes com esclerose lateral amiotrófica. Rev CEFAC. 2017;19(5): 664-73. Doi: https://doi.org/10.1590/1982-021620171954017
Xerez DR. Reabilitação na esclerose lateral amiotrófica: revisão de literatura. Acta Fisiatr. 2008;15(3):182-8.
Recabarren-Leiva D, Alarcón M. New insights into the gene expression associated to amyotrophic lateral sclerosis. Life Sci. 2018;193:110-23. Doi: https://doi.org/10.1016/j.lfs.2017.12.016
Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218-26. Doi: https://doi.org/10.1212/WNL.0b013e3181bc0141
Costa FA, Martins LJNS, Silva NPO. A esclerose lateral amiotrófica e a fisioterapia motora [texto na Internet]. São Paulo; IPG; c2016 [citado 2020 Ago 5]. Disponível em: http://www.todosporela.org.br/site/downloads/7df03136dec0f63e5b2be9f29600b549.pdf
Pozza AM, Delamura MK, Ramirez C, Valério NI, Marino LH, Lamari NM. Conduta fisioterapêutica na esclerose lateral amiotrófica. Sao Paulo Med J. 2006;124(6):350-4. Doi: https://doi.org/10.1590/s1516-31802006000600011
Linden Junior E. Abordagem fisioterapêutica na esclerose lateral amiotrófica: artigo de atualização. Rev Neurocienc 2013;21(2):313-18. Doi: https://doi.org/10.4181/RNC.2013.21.803.6p
Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional por Amostra de Domicílios Contínua: características gerais dos moradores: 2012-2016. Rio de Janeiro: IBJE; 2017.
Rossi PG, Farche ACS, Ansai JH, Takahashi ACM, Mascarenhas MA. Perfil de idosos admitidos em serviço de fisioterapiafrente à sazonalidade. Scientia Med. 2017;27(2):ID24994. Doi: https://doi.org/10.15448/1980-6108.2017.2.24994
Cavalcanti G, Doring M, Portella MR, Bortoluzzi EC, Mascarelo A, Dellani MP. Multimorbidade associado à polifarmácia e autopercepção negativa de saúde. Rev Bras Geriatr Geront. 2017;20(5):634-42. Doi: http://dx.doi.org/10.1590/1981-22562017020.170059
Brettschneider J, Kurent J, Ludolph A, Mitchell JD. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2008;(3):CD005226. Doi: https://doi.org/10.1002/14651858.CD005226.pub2
Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;(2):CD004156. Doi: https://doi.org/10.1002/14651858.CD004156.pub4
Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;(4):CD004157. Doi: https://doi.org/10.1002/14651858.CD004157.pub2
Sanjak M, Langford V, Holsten S, Rozario N, Patterson CGM, Bravver E, et al. Six-Minute walk test as a measure of walking capacity in ambulatory individuals with amyotrophic lateral sclerosis. Arch Phys Med Rehabil. 2017;98(11):2301-7. Doi: https://doi.org/10.1016/j.apmr.2017.04.004
Orsini M, Freitas MRG, Mello MP, Antonioli ES, Reis JPB, Nascimento OJM, et al. Reabilitação física na esclerose lateral amiotrófica. Rev Neurocienc. 2009:17(1):30-6. Doi: https://doi.org/10.34024/rnc.2009.v17.8601
Facchinetti LD, Orsini M, Lima MASD. Os riscos do exercício excessivo na ELA: atualização da literatura. Rev Bras Neurol. 2009; 45(3):33-8.
Honorato ES, Martins EF. Evidências para direcionamento da intervenção fisioterapêutica nas alterações cinético-funcionais geradas pela esclerose lateral amiotrófica. Rev Bras Ciên Saúde. 2008;6(15):66-74. Doi: https://doi.org/10.13037/rbcs.vol6n15.541
Kioumourtzoglou MA, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG. Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):224-9. Doi: https://doi.org/10.3109/21678421.2014.988161
Carratù P, Spicuzza L, Cassano A, Maniscalco M, Gadaleta F, Lacedonia D, et al. Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency. Orphanet J Rare Dis. 2009;4:10. Doi: https://doi.org/10.1186/1750-1172-4-10
Sathyaprabha TN, Pradhan C, Nalini A, Thennarasu K, Raju TR. Pulmonary function tests and diaphragmatic compound muscle action potential in patients with sporadic amyotrophic lateral sclerosis. Acta Neurol Scand. 2010;121(6):400-5. Doi: https://doi.org/10.1111/j.1600-0404.2009.01199.x
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Acta Fisiátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
